Recent Updates
Recently added Catalysts

GSK3772701

Phase 2

Malaria, Falciparum | Small molecule | Infectious Disease |GSK plc|Last Updated: Apr 22, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
CONTROLLEDBiomarker
Total Trials1
Total Enrollment70
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07545681A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum MalariaPHASE2 NOT YET_RECRUITING 70Apr 20, 2026Jul 22, 2027Apr 22, 2026 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of participants with serious adverse events (SAEs) overall, treatment related, and by severity
From the date of informed consent signing (up to 24 hours prior to Day 1) up to Day 40 (end of the follow-up period)

A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant; abnormal pregnancy outcomes; or any other situation according to medical or scientific judgment. The intensity of SAEs is assessed as per the Division of Acquired Immunodeficiency Syndrome (DAIDS) criteria Version 2.1 where grades are defined based on numeric criteria as follows Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: potentially life-threatening; Grade 5: death. A higher grade indicates greater severity. Any = occurrence of the event regardless of intensity grade and treatment relationship. Treatment related = occurrence of the event which, in the investigator's opinion, is related to the administered treatment regardless of the intensity grade.

Number of participants with non-serious AEs overall, treatment related, and by severity
From Day 1 up to Day 40

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The intensity of non-serious AEs is assessed using the DAIDS criteria Version 2.1 where grades are defined based on numeric criteria as follows Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: potentially life-threatening; Grade 5: death. A higher grade indicates greater severity. Any = occurrence of the event regardless of intensity grade and treatment relationship. Treatment related = occurrence of the event which, in the investigator's opinion, is related to the administered treatment regardless of the intensity grade.

Secondary Endpoints
Area under the concentration (AUC) - time curve (AUC[0-t]) of GSK3772701
From Day 1 to Day 7
AUC(0-t) extrapolated to infinity (AUC[0-inf]) of GSK3772701
From Day 1 to Day 7
Maximum observed concentration (Cmax) of GSK3772701
From Day 1 to Day 7
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Cohort 1_Single DoseEXPERIMENTALParticipants receive a single GSK3772701 600 mg dose on Day 1.
Cohort 2_ Single DoseEXPERIMENTALParticipants receive a single GSK3772701 900 mg dose on Day 1.
Cohort 3_ Repeat DoseEXPERIMENTALParticipants receive a daily 150 mg dose of GSK3772701 on Day 1 and Day 2.
Cohort 4_ Repeat DoseEXPERIMENTALParticipants receive a daily 400 mg dose of GSK3772701 on Day 1 and Day 2.
Cohort 5_ Repeat DoseEXPERIMENTALParticipants receive a daily 50 mg dose of GSK3772701 on Day 1, Day 2 and Day 3.
Interventions
NameTypeDescription
GSK3772701 600 mgDRUGA 600 mg dose of GSK3772701 administered orally, as 4 capsules of 150 mg.
GSK3772701 900 mgDRUGA 900 mg dose of GSK3772701 administered orally, as 6 capsules of 150 mg.
GSK3772701 150 mgDRUGA daily 150 mg dose of GSK3772701 administered orally on Day 1 and Day 2, as 1 capsule.
GSK3772701 400 mgDRUGA daily 400 mg dose of GSK3772701 administered orally on Day 1 and Day 2, as 2 capsules of 150 mg and 1 capsule of 100 mg.
GSK3772701 50 mgDRUGA daily 50 mg dose of GSK3772701 administered orally on Day 1, Day 2 and Day 3, as 1 capsule.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Male and female patients aged 18 to 65 years. * Presence of malaria due to mono-infection with P. falciparum confirmed by: * Fever, as defined by axillary temperature \>=37.5°C or oral/tympanic temperature \>=38°C and, * Microscopically confirmed P. falciparum malaria par...

Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT07545681primaryCompletionDate: changed
LOWMay 24, 2026NCT07545681studyFirstPostDate: changed
LOWMay 21, 2026NCT07545681NEW_TRIAL: changed
LOWMay 21, 2026NCT07545681NEW_TRIAL: changed